Key clinical point: Psoriasis or psoriatic arthritis with previous exposure to biologics had no significant difference in serious infection risk based on biologic type.
Major finding: The risk of serious infection was 41% lower in biologic-naive patients treated with an interleukin-12/23 inhibitor, compared with those treated with TNF inhibitor.
Study details: The data come from a retrospective study of 11,560 treatment episodes for psoriasis or psoriatic arthritis in 9,305 adults.
Disclosures: The study was supported by the Center for Drug Safety and Effectiveness at the Johns Hopkins Bloomberg School of Public Health. The researchers had no financial conflicts to disclose.
Li X et al. Ann Rheum Dis. 2019 Oct 31. doi: 10.1136/annrheumdis-2019-216102.